Staar Surgical Company
Open
$26.16
Prev. Close
$26.18
High
$26.20
Low
$26.16
Market Snapshot
$1.27B
-15.8
-0.42
$313.9M
957
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
emptyResult
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Recently from Cashu
STAAR 2.0: Transforming AI Compliance for Staar Surgical and Other Companies
Advancing Compliance in AI: The Launch of STAAR 2.0 In the rapidly evolving landscape of artificial intelligence (AI), legal compliance remains paramount. Staar Surgical Company, as a key player in th…
Debevoise Launches STAAR 2.0: A New AI Compliance Tool for Legal Teams
Navigating AI Compliance: The Launch of STAAR 2.0 by Debevoise & Plimpton In a notable advancement for the legal technology landscape, Debevoise & Plimpton LLP unveils STAAR 2.0, an enhanced version o…
Staar Surgical Posts Strong Q4 Earnings, Driven by Innovative Eye Surgery Products
Staar Surgical Charts a Course for Growth Through Innovation in Eye Care Staar Surgical Company announces its fourth-quarter earnings for 2026, showcasing a substantial financial performance driven by…
Staar Surgical Set to Report Earnings, Showcasing Innovations in Ophthalmic Devices
Staar Surgical Poised for Earnings Report Highlighting Innovations in Ophthalmic Devices Staar Surgical Company, a prominent player in the ophthalmic device industry, prepares to unveil its quarterly…